Test early immune-tolerance treatment for matched kidney transplant patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and already have a living kidney transplant from an HLA-matched donor
- Your transplant happened between 3 months and 5 years before the planned infusion
- You have NOT had rejection in your current matched kidney transplant
- You have no major post-transplant problems like active infection or a new serious cancer
- You must be able to travel to UCLA within 3 hours for the first 3–6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
Hear when a new End Stage Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.